OncoSil | transforming the prognosis

OncoSil™

OncoSil™ System for Healthcare Professionals

OncoSil™ is a single-use brachytherapy device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. It is used in addition to chemotherapy.¹

Discover more

At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo.

Learn more about our people

We believe in our technology and its ability
to have a truly positive impact in Oncology.

Latest news

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and Encouraging Clinical

OncoSil Medical Receives TGA Approval for OncoSil Device in

OSPREY Registry Interim Results Presented at ESGE Days

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and ...

OncoSil Medical Receives TGA Approval for OncoSil Device in ...

OSPREY Registry Interim Results Presented at ESGE Days ...

View all news

Investor Resources

At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.

Investor resource home

Annual Report 2026

Read Here

References:

1. The OncoSil™ System is intended to induce prolonged local tumour control and tumoursize reduction in patients with locally advanced unresectable pancreatic cancer, in addition to gemcitabine-based chemotherapy, by implantation of radioactive Phosphorous-32 Microparticles into pancreatic tumours under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in addition to gemcitabine-based chemotherapy.

Want to learn more?

OncoSil™ is a brachytherapy device that utilises targeted intratumoural placement of Phosphorous 32 microparticles, delivered via ultrasound-guided endoscopy.

Learn about our mode of action

Cookie	Duration	Description
__cf_bm	1 hour	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_cfuvid	session	Calendly sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
rc::a	Never	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
XSRF-TOKEN	2 hours	This cookie enhances visitor browsing security by preventing cross-site request forgery.

Cookie	Duration	Description
li_gc	6 months	Linkedin set this cookie for storing visitor's consent regarding using cookies for non-essential purposes.
lidc	1 day	LinkedIn sets the lidc cookie to facilitate data center selection.

Cookie	Duration	Description
_ga	13 months	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_*	13 months	Google Analytics sets this cookie to store and count page views.

Cookie	Duration	Description
share_link_session	session	No description available.
SRVNAME	past	No description available.

Improving outcomes for people
with pancreatic cancer

OncoSil™

We believe in our technology and its ability
to have a truly positive impact in Oncology.

Latest news

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and Encouraging Clinical

OncoSil Medical Receives TGA Approval for OncoSil Device in

OSPREY Registry Interim Results Presented at ESGE Days

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and ...

OncoSil Medical Receives TGA Approval for OncoSil Device in ...

OSPREY Registry Interim Results Presented at ESGE Days ...

Investor Resources

Annual Report 2026

Want to learn more?

Head office

Renzo DiCarlo

Nigel Lange

Dr Martin Cross

David James

Professor Ricky Sharma

Dr Martin Cross

Lel Smits

Douglas Cubbin

Thomas Duthy

Gabriel Liberatore

Mr Brian Leedman

Henk Tissing

David Turner

Nicole Wilson

Jon Bell

Shelley Steyn

Christian Dal Cin

Nigel Lange

Notice:

Improving outcomes for people with pancreatic cancer

OncoSil™

We believe in our technology and its ability to have a truly positive impact in Oncology.

Latest news

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and Encouraging Clinical

OncoSil Medical Receives TGA Approval for OncoSil Device in

OSPREY Registry Interim Results Presented at ESGE Days

TRIPP-FFX Results Presented at ESMO GI 2026 Reinforce Safety and ...

OncoSil Medical Receives TGA Approval for OncoSil Device in ...

OSPREY Registry Interim Results Presented at ESGE Days ...

Investor Resources

Annual Report 2026

Want to learn more?

Improving outcomes for people
with pancreatic cancer

We believe in our technology and its ability
to have a truly positive impact in Oncology.